Mitochondrial Reprogramming of Peripheral Blood Insulin-Producing Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic medical conditions such as diabetes and cancers are largely ineffective, and existing stem cell therapies face challenges like immune rejection, limited cell availability, and graft-versus-host disease, necessitating a method to generate autologous multipotent cells for regenerative medicine.
Innovation Solution
The method involves isolating adult human peripheral blood insulin-producing cells and exposing them to platelet-derived mitochondria, which reprogram these cells into multipotent stem cells capable of differentiating into various cell lineages, including insulin-producing cells and hematopoietic stem cells, thereby overcoming the limitations of conventional stem cell therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If embryonic stem cells or induced pluripotent stem cells are used for regenerative medicine, then cell regeneration potential is improved, but immune rejection risk increases
Solution Approach 1:
The patent applies self-service by using the patient's own peripheral blood cells as the starting material for generating therapeutic stem cells. This autologous approach ensures that the resulting multipotent cells will not be rejected by the patient's immune system, as they are genetically identical to the patient's existing cells. The process involves isolating insulin-producing cells from the patient's blood and reprogramming them using platelet-derived mitochondria, creating a self-sustaining therapeutic product that eliminates immune rejection risks.
2Adaptability or versatility
If conventional stem cell transplantation is performed, then treatment for chronic conditions is improved, but graft-versus-host disease risk increases
Solution Approach 1:
The patent eliminates graft-versus-host disease risk by using autologous cells - the patient's own peripheral blood cells are isolated and reprogrammed to generate multipotent stem cells. Since these cells are genetically identical to the patient's host cells, there is no foreign immune response or graft-versus-host disease. The process uses the patient's body to create therapeutic cells that will naturally integrate without causing immune-mediated harm.
3Quantity of substance
If pancreas and islet transplantations are performed to overcome insulin shortage, then insulin production is improved, but donor scarcity and immune rejection increase
Solution Approach 1:
The patent applies self-service by extracting insulin-producing cells from the patient's own peripheral blood and reprogramming them to expand their population. This autologous expansion approach eliminates the need for donor pancreases or islets, as the patient's body provides the source cells. The process involves isolating insulin-producing cells from peripheral blood, treating them with platelet-derived mitochondria to enhance their regenerative capacity, and expanding them in culture to generate sufficient insulin-producing cells without requiring external donors.
Solution Approach 2:
The patent uses parameter changes by altering the regenerative capacity and proliferative potential of insulin-producing cells through mitochondrial treatment. By introducing platelet-derived mitochondria, the cells undergo epigenetic reprogramming that changes their developmental potential, enabling them to differentiate into various cell types and expand their population. This parameter change in cellular potential allows the cells to transition from a limited, adult state to a more versatile, regenerative state.
4Ease of operation
If adult peripheral blood cells are used for therapy, then ease of cell acquisition is improved, but cell multipotency is limited
Solution Approach 1:
The patent applies parameter changes by using mitochondrial treatment to alter the epigenetic state and regenerative potential of adult peripheral blood cells. This treatment changes the cells from a differentiated, limited-potential state to a multipotent, regenerative state. The mitochondrial intervention reprograms gene expression patterns and cellular identity, enabling adult cells to differentiate into various tissue types while maintaining the ease of acquisition from peripheral blood.
Solution Approach 2:
The patent uses platelet-derived mitochondria as an intermediary substance to transfer regenerative potential and epigenetic information to adult peripheral blood cells. These mitochondria act as a mediator that carries the necessary factors to reprogram host cells, enabling the transfer of multipotency without direct cell-to-cell contact or genetic modification of the host genome. The mitochondria serve as a vehicle for delivering the regenerative program to the target cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the efficient generation of autologous multipotent cells that can differentiate into multiple cell types, potentially treating diabetes and other conditions without immune rejection issues, and demonstrates high potential for regenerative medicine by reprogramming PB-IPC into miPB-IPC and miCD34+ HSC, enhancing cell therapy outcomes.
Implementation Method 1
exposing them to platelet-derived mitochondria, which reprogram these cells into multipotent stem cells
Implementation Method 2
allowing the cells to be reprogrammed, transforming PB-IPC into multipotent stem cells giving rise to three germ layer-derived cells
Data Source
AI summary
A method of generating multipotent stem cells from adult human peripheral blood cells by isolating the peripheral blood insulin-producing cells and exposing them to adult peripheral blood-derived mitochondria. Adult peripheral blood insulin-producing cells (PB-IPC) are isolated from adult peripheral blood by adherence to a hydrophobic surface with a positive charge, such as a Petri dish. Once the PB-IPC are isolated, mitochondria derived from adult peripheral blood are applied to the isolated PB-IPC. The mitochondria are then taken in by the PB-IPC and enter the nuclei of the PB-IPC, allowing the cells to be reprogrammed, transforming PB-IPC into multipotent stem cells and giving rise to three germ layer-derived cells. Additionally, PB-IPC give rise to functional CD34+ hematopoietic stem cell (HSC)-like cells after treatment with adult peripheral blood-derived mitochondria.